| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:184.)
© 2001 American Heart Association, Inc.
Original Contributions |
From the Departments of Internal Medicine and Pharmacology, Cardiovascular Center, and Radiation Research Laboratory (L.W.O.), University of Iowa College of Medicine, Iowa City.
Correspondence to Donald D. Heistad, MD, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA 52242. E-mail donald-heistad{at}uiowa.edu
| Abstract |
|---|
|
|
|---|
MethodsWe injected recombinant adenoviruses expressing EC-SOD (AdEC-SOD), CuZnSOD (AdCuZnSOD), or ß-galactosidase (Adß-gal) into the cisterna magna of rabbits.
ResultsTotal SOD activity in CSF was 39±11 U/mL (mean±SE) before virus injection. Three days later, total SOD activity in CSF increased to 148±22 U/mL after AdEC-SOD and 92±10 U/mL after AdCuZnSOD (P<0.05 versus AdEC-SOD), with no change after Adß-gal (49±5 U/mL). EC-SOD protein was detected in CSF after AdEC-SOD but not AdCuZnSOD or Adß-gal. Injection of heparin or dextran sulfate into the cisterna magna increased total SOD activity 27-fold and 32-fold over basal values, respectively, in CSF of rabbits that received AdEC-SOD. In contrast to effects in CSF, total SOD activity in basilar artery and meninges was significantly higher after AdCuZnSOD and tended to be higher after AdEC-SOD than after Adß-gal.
ConclusionsWe have developed a method for intracranial gene transfer of CuZnSOD and EC-SOD. After gene transfer, CuZnSOD was expressed mainly in tissues, and EC-SOD was released into the CSF, especially after injection of heparin or dextran sulfate. Gene transfer of different isoforms of SOD may be useful in studies of cerebral vascular physiology and pathophysiology.
Key Words: adenovirus basilar artery gene transfer heparin superoxide dismutase
| Introduction |
|---|
|
|
|---|
There are 3 known isoforms of SOD: copper-zinc SOD (CuZnSOD), manganese SOD (MnSOD), and extracellular SOD (EC-SOD). CuZnSOD is an isoform of SOD that exists intracellularly and dismutes superoxide within cells.7 8 MnSOD is located in mitochondria and plays a critical role as an antioxidant.8 9 EC-SOD is the only isoform of SOD that is released from cells into the extracellular space.10 EC-SOD is the primary extracellular antioxidant enzyme and is highly expressed in blood vessels,11 12 uterus,13 and airways.12 We speculated that, after intracranial gene transfer of CuZnSOD, CuZnSOD would remain within cells lining the subarachnoid space and SOD activity would increase within the cells. In contrast, we anticipated that after intracranial gene transfer of EC-SOD, EC-SOD would be produced within the cells and released into extracellular space. Thus, SOD activity might increase in both cells and cerebrospinal fluid (CSF).
Previous studies have reported that EC-SOD is released into plasma from liver after injection of heparin or dextran sulfate intravenously.14 The mechanism of this release is thought to be displacement of EC-SOD by heparin or dextran sulfate from heparan sulfate proteoglycan on cell surfaces.15 We speculated that heparin or dextran sulfate might release EC-SOD into CSF after transduction of EC-SOD to cells in the subarachnoid space.
Our goals were (1) to determine whether gene transfer of CuZnSOD and EC-SOD by injection into the cisterna magna increases SOD activity in cells lining the subarachnoid space and in CSF, (2) to determine whether the increase in SOD activity in CSF is greater after gene transfer of EC-SOD than CuZnSOD, and (3) to determine whether heparin or dextran sulfate enhances release of EC-SOD into the CSF.
| Materials and Methods |
|---|
|
|
|---|
In Vivo Gene Transfer to Rabbits
All animal procedures were approved by the Animal
Care and Use Review Committee at the University of Iowa. Adult male New
Zealand White rabbits (weight, 2.5 to 3.4 kg; n=34) were
anesthetized with intramuscular ketamine 50 mg/kg and
xylazine 10 mg/kg. A 25-gauge needle was aseptically inserted into the
cisterna magna as previously
described,17 Three hundred
microliters of CSF was withdrawn for measurement of total SOD activity,
and 300 µL of viral suspension (artificial CSF with Adß-gal,
AdCuZnSOD, or AdEC-SOD in 3% sucrose) was injected slowly. The dose of
adenovirus was 3x109 plaque-forming units
per injectate.
We observed the distribution of ß-gal expression in the brain of rabbits using X-gal staining after injection of AdCMVß-gal into the cisterna magna. We found that the ventral surface of the brain was extensively stained in rabbits (data not shown), as we had shown previously in rats,17 mice,18 and rabbits.19
One day after injection of virus suspension, rabbits were anesthetized with intramuscular ketamine 50 mg/kg and xylazine 10 mg/kg, and CSF was collected. Three days after injection, rabbits were killed by an overdose of pentobarbital. After collection of CSF, the basilar artery and meninges (dura) of the brain stem were obtained. Each CSF sample was centrifuged at 3000 rpm for 6 minutes to remove cell components. Supernatant was stored at -20°C until used. Basilar artery and meninges were frozen in liquid nitrogen and stored at -80°C until used.
In some rabbits, heparin (20 U/kg) or dextran sulfate (5000 molecular weight, 8 µg/kg) was injected into the cisterna magna 3 days after gene transfer of EC-SOD or CuZnSOD, and CSF samples were collected 15, 60, and 120 minutes after injection of heparin or dextran sulfate. We estimated the dose of heparin and dextran sulfate from a previous study, in which 2000 U/kg of heparin and 800 mg/kg of dextran sulfate were injected intravenously.14 Total blood volume is approximately 100x CSF volume, and we therefore injected a dose of heparin and dextran sulfate into CSF based on the ratio of the volume of blood and CSF. Total SOD activity was measured in the samples by the nitroblue tetrazolium (NBT) method.20
Immunocytochemistry for EC-SOD
Unfixed frozen arteries were cut into 6-µm sections
on a cryostat at -20°C. Sections were incubated with primary
antibody (goat anti-human EC-SOD, 1:500) overnight. After they were
washed with PBS, sections were incubated for 30 minutes with the
secondary antibody (mouse anti-goat IgG, 1:1000), rinsed again with
PBS, and developed with Vectastain ABC Kit alkaline phosphatase (Vector
Laboratories Inc).
Total SOD Activity
Tissue Preparation
Transduced basilar arteries and meninges were
homogenized with a tissue homogenizer
(5-second bursts for 3 minutes) in 3 volumes of 0.05 mol/L phosphate
buffer, pH 7.8, and sonicated with an ultrasonic processor (10-second
bursts for 1 minute). All procedures were performed on ice. The
homogenate was centrifuged at 3000 rpm for 10
minutes, and the supernatant was used for determination of protein
content and total SOD activity.
SOD Assay
Total SOD activities of tissue and CSF were
determined by the method of Spitz and
Oberley.20 Measurement of
enzyme activity was based on inhibition of
O2-mediated
reduction of NBT to formazan, the photoabsorbant product. Solutions
containing 1 U/mL catalase,
5.6x10-5 mol/L
NBT, 0.1 mmol/L xanthine, 1.0 mmol/L
diethylenetriaminepentaacetic acid, 0.13 mg/mL bovine serum
albumin, and 50 µmol/L bathocuproine disulfonic acid in 0.05
mol/L phosphate buffer (pH 7.8) were incubated with varying amounts of
supernatant (0 to 100 µg of protein in tissue samples, 0 to 100 µL
in CSF samples). Superoxide radicals were generated by adding xanthine
oxidase (10-2
to 10-3 U/mL)
to the cuvettes, and measurements were recorded at 560 nm, 37°C
for 5 minutes, with the use of a spectrophotometer. Total SOD activity
of the supernatant was measured as the effectiveness of the supernatant
to inhibit dismutation of
O2- generated by
the xanthinexanthine oxidase reaction. Total SOD activities were
expressed in units per milligram of protein measured, as described by
Lowry et al,21 for tissue
samples or units per milliliter for CSF
samples.
Western Blotting for CuZnSOD and EC-SOD in
CSF
To determine the isoforms of SOD in CSF, Western
blotting was used. First, CSF samples were concentrated 10-fold by
cryovaporization. CSF that contained 50 µg of protein was denatured
with SDS loading buffer at 95°C for 5 minutes and then separated on
an SDS/10% polyacrylamide gel with 5% stacking gel in
SDS/Tris/glycine running
buffer.22 We used a
commercial CuZnSOD standard (Sigma) and made an EC-SOD standard using
gene transfer with AdEC-SOD to C6 glioma cells. The protein was
electrophoretically transferred to a nitrocellulose membrane, which was
then blocked with 5% (wt/vol) nonfat milk in PBS containing 0.1%
Tween-20 for 1 hour at room temperature. The membrane was then
incubated with primary antibody, goat anti-human EC-SOD (1:5000), or
sheep anti-human CuZnSOD (1:500) in PBS containing 0.1% Tween-20 for 1
hour. After it was washed, the blot was incubated with horseradish
peroxidaseconjugated rabbit anti-goat IgG (1:10 000) or rat
anti-sheep IgG (1:10 000) for 1 hour at room temperature. After it was
washed, the blot was incubated with Super Signal ULTRA chemiluminescent
substrate (Pierce Laboratories) and exposed to x-ray
film.
Data Analysis
Results are expressed as mean±SE. Total SOD activity
data in CSF, basilar arteries, and meninges were analyzed with
1-way ANOVA with post hoc Bonferroni
correction.
| Results |
|---|
|
|
|---|
|
After injection of AdCuZnSOD into the cisterna magna,
total SOD activity of basilar arteries was 2.5 times higher than that
after injection of Adß-gal. Total SOD activity of basilar artery
tended to increase after gene transfer of AdEC-SOD but was not
significantly higher than that after Adß-gal
(Figure 2
).
|
Results were similar in the meninges. SOD activity in
meninges was significantly higher 3 days after gene transfer of CuZnSOD
than after EC-SOD or ß-gal
(Figure 2
).
SOD in CSF
There was no significant difference among the 3 groups
in basal levels of total SOD activity in CSF. Three days after gene
transfer of AdEC-SOD, total SOD activity was >3 times higher than
basal level and was significantly higher than after injection of
Adß-gal or AdCuZnSOD
(Figure 3
). Total SOD activity tended to increase after
injection of AdCuZnSOD compared with Adß-gal, but this was not
statistically significant.
|
Western blotting of EC-SOD showed a band in CSF at the
same position as the EC-SOD standard after injection of AdEC-SOD
(Figure 4
). This band was not detected in CSF samples from
rabbits that were treated with AdCuZnSOD or Adß-gal. In contrast,
CuZnSOD protein was undetectable in any samples of CSF. This result
indicates that there is no detectable CuZnSOD protein in CSF even after
gene transfer of CuZnSOD.
|
Effects of Heparin and Dextran Sulfate
After transduction with AdEC-SOD, injection of heparin
into the cisterna magna of rabbits increased total SOD activity by
6.7-fold, which was 27-fold the basal value for total SOD activity
(Figure 5
, left panel). The elevation was sustained for at
least 2 hours after injection of heparin.
|
After transduction with AdEC-SOD, injection of dextran
sulfate increased total SOD activity by 7.4-fold, which was a 33-fold
increase above basal value in total SOD activity
(Figure 5
, right panel). Injection of heparin or dextran
sulfate in rabbits that received AdCuZnSOD did not significantly
increase total SOD activity in CSF.
| Discussion |
|---|
|
|
|---|
Immunocytochemistry of EC-SOD showed extensive staining in the adventitia of basilar artery from rabbits that received AdEC-SOD. Furthermore, total SOD activity in basilar artery and meninges from rabbits that received AdCuZnSOD increased significantly compared with ß-gal transducedrabbits. These results indicate that CuZnSOD and EC-SOD can be transduced in the basilar artery and meninges by injection of adenoviral vectors into the cisterna magna. In this study we used anti-human EC-SOD antibody, which detects human but not rabbit EC-SOD. Thus, we could detect the EC-SOD that is expressed by gene transfer by immunocytochemistry and Western blotting.
EC-SOD is the only isoform of SOD that is released into the extracellular space.10 Because the amount of EC-SOD in most organs is relatively small compared with CuZnSOD and MnSOD, it has been assumed that this enzyme does not play a major role in dismutation of superoxide in extracellular space.23 However, recent studies indicate that in some tissues, such as blood vessels,11 12 uterus,13 and airways,12 EC-SOD is the predominant isoform of SOD. Thus, effects of EC-SOD under physiological and pathological conditions are of interest. Recently, several studies using EC-SOD transgenic mice have reported that EC-SOD has neuroprotective effects24 and anti-inflammatory effects.25
EC-SOD has a heparin binding site and can bind to heparan sulfate proteoglycans on the cell surface. On the basis of affinity for heparin, EC-SOD is separated into type A (without affinity), type B (with weak affinity), and type C (with high affinity) for heparin.10 There are large interspecies differences in total plasma EC-SOD activity and affinity for heparin.26 EC-SOD of rats is mainly present in the extracellular fluid because rats have no type C EC-SOD. On the other hand, as predicted from the affinity for heparin, EC-SOD of humans (type C) binds to the cell surface. In rabbits, type C is the predominant isoform of EC-SOD.26
In this study we transduced human EC-SOD to the brain of rabbits. Thus, human EC-SOD was overexpressed in cells and released into the extracellular space and then presumably bound to extracellular matrix of tissues. Immunocytochemistry for EC-SOD demonstrated that human EC-SOD was expressed in the adventitia of basilar artery and meninges after gene transfer. Interestingly, and as anticipated, total SOD activity in CSF also increased after injection of AdEC-SOD. On the basis of the Western blotting, the increase of SOD activity was due to expression of human EC-SOD. There may be several explanations for the presence of human EC-SOD in CSF after gene transfer. First, although the majority of human EC-SOD is type C, type A and type B of EC-SOD may also be present.26 Thus, these types of SOD, especially type B, may be released into the CSF. Second, the binding of type C EC-SOD for heparan sulfate proteoglycans on the cell surface appears to be rather loose compared with other proteins that bind to heparan sulfate proteoglycans.15 Thus, some amount of type C EC-SOD may be released into the CSF by heparin.
Injection of heparin or dextran sulfate into the
cisterna magna produced a large increase of total SOD activity in CSF
in rabbits after gene transfer of EC-SOD but not CuZn-SOD. Because
total SOD activity is measured in CSF, the values represent
both endogenous and exogenous SOD. Thus, the minimal
increase in SOD activity shown in
Figure 5
, after heparin or dextran sulfate in rabbits that
received AdCuZn-SOD, indicates that neither exogenous nor
endogenous isoforms increased substantially. We speculate
that heparin and dextran sulfate bind to the heparin binding site of
EC-SOD and displace EC-SOD into CSF from cells lining the
subarachnoid space. This result is consistent with a
previous report that showed an increase in SOD activity in plasma after
gene transfer of EC-SOD and injection of heparin or dextran sulfate
intravenously.14
It is likely that, after injection of AdEC-SOD into the cisterna magna, some EC-SOD was released into the CSF, but the majority of the EC-SOD was bound to the extracellular matrix of tissues. Heparin and dextran sulfate then presumably displaced EC-SOD, which was bound to cells, from extracellular matrix into extracellular fluid. In a previous report, a 3-fold increase in CuZnSOD in neurons of transgenic mice had a protective effect against glutamate neurotoxicity.27 In other reports, a 3- to 5-fold increase in EC-SOD in the brain or lung of transgenic mice had a protective effect against cerebral ischemia24 or hyperoxic toxicity.25 Thus, we anticipate that, although SOD activity in CSF is normally low, a 25- to 30-fold increase in SOD activity after gene transfer may be effective against oxidative stress produced by pathophysiological conditions such as subarachnoid hemorrhage, meningitis, or acute hypertension.
In contrast, gene transfer of CuZnSOD produced a substantial increase in SOD activity in tissues, with only a small increase in CSF. This finding is consistent with the concept that CuZnSOD is produced within cells and, after gene transfer, largely remains intracellular. However, total SOD activity in CSF tended to increase after gene transfer of CuZnSOD. One possible mechanism for the increase in SOD activity in CSF is that some cells, which were infected with AdCuZnSOD, may have undergone cell death, and endogenous rabbit SOD was released into the CSF. Because no human CuZnSOD protein was detected in CSF by Western blotting after gene transfer of CuZnSOD, it is unlikely that the elevation of SOD activity was produced by human SOD that was transduced to the rabbits.
As discussed above, it is most likely that the higher activity of SOD in CSF after gene transfer of EC-SOD than CuZnSOD is due to release of EC-SOD, but not CuZnSOD, from the extracellular compartment into the CSF. It is possible, however, that both SODs are released into CSF, and more rapid clearance of the smaller protein (CuZnSOD) contributes to low concentrations in CSF.
CuZnSOD may play an important role in protection against neuronal injury1 2 3 and vasospasm after subarachnoid hemorrhage.5 CuZnSOD improves vasomotor function28 29 30 by dismutation of superoxide anion within cells. Several reports have suggested that increases in intracellular CuZnSOD, using liposomal-encapsulated SOD31 32 33 or polyethylene glycol conjugated SOD,29 30 are effective in protection of cells. Using gene transfer techniques, CuZnSOD can be overexpressed within cells. Thus, gene transfer of CuZnSOD also appears to be a promising approach to protect vessels from pathological conditions.
Efficiency of gene transfer varies among species and may be influenced by serotype of adenoviral vectors that is used for different species. Applications of this approach to different species, including humans, will require optimization of the vector, including perhaps the serotype of the adenovirus.
Studies using transgenic mice suggest that CuZnSOD and EC-SOD are key enzymes in protection against neuronal injury or vasomotor dysfunction.1 5 24 28 Furthermore, EC-SOD may be involved in regulation of vasomotor function34 because there are substantial amounts of EC-SOD in blood vessels.11 12 We suggest that this intracranial in vivo gene transfer approach may be useful in clarifying the role of EC-SOD and CuZnSOD in cerebral vascular biology.
| Acknowledgments |
|---|
Received April 25, 2000; revision received September 8, 2000; accepted September 8, 2000.
| References |
|---|
|
|
|---|
Neurosurgical Laboratories, Stanford University, Stanford, California
| Introduction |
|---|
|
|
|---|
Although transgenic or knockout mice of these SOD isoforms have been generated and used in stroke studies,R3 R4 R5 R6 it is not clear whether these enzymes can be expressed and upregulated by means other than the transgenic technology. In this nicely written and carefully done study, Nakane and his colleagues have injected an adenoviral vector with either the CuZn SOD or EC SOD gene into the cerebrospinal fluid and then looked at the distribution and expression pattern in brain tissue. The same group of investigators have used this gene transfer technique in vivo to cerebral blood vessels and perivascular tissue in mice.R7 They have demonstrated that increased CuZn SOD activity was detected in brain tissue, whereas increased EC SOD activity was found only in the cerebrospinal fluid. Thus, the authors have successfully developed a method for intracranial gene transfer of CuZn SOD and EC SOD that can target the intracellular or extracellular compartments, respectively. In view of the importance of oxidative stress in cerebral vascular responses after cerebral ischemia and reperfusion, this method of gene transfer of different isoforms of SOD at different cellular locations is extremely useful to dissect out the divergent roles of these isoforms in signaling and neuroprotection in ischemic brain damage.
Received April 25, 2000; revision received September 8, 2000; accepted September 8, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. Kitayama, C. Yi, F. M. Faraci, and D. D. Heistad Modulation of Dilator Responses of Cerebral Arterioles by Extracellular Superoxide Dismutase Stroke, November 1, 2006; 37(11): 2802 - 2806. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yamaguchi, C. Zhou, D. D. Heistad, Y. Watanabe, and J. H. Zhang Gene Transfer of Extracellular Superoxide Dismutase Failed to Prevent Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage Stroke, November 1, 2004; 35(11): 2512 - 2517. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Bivalacqua, J. S. Armstrong, J. Biggerstaff, A. B. Abdel-Mageed, P. J. Kadowitz, W. J. G. Hellstrom, and H. C. Champion Gene transfer of extracellular SOD to the penis reduces O Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1408 - H1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Watanabe, Y. Chu, J. J. Andresen, H. Nakane, F. M. Faraci, and D. D. Heistad Gene Transfer of Extracellular Superoxide Dismutase Reduces Cerebral Vasospasm After Subarachnoid Hemorrhage Stroke, February 1, 2003; 34(2): 434 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P. Didion, M. J. Ryan, L. A. Didion, P. E. Fegan, C. D. Sigmund, and F. M. Faraci Increased Superoxide and Vascular Dysfunction in CuZnSOD-Deficient Mice Circ. Res., November 15, 2002; 91(10): 938 - 944. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |